Supernus Pharma (SUPN) Tops Q2 EPS by 23c

Supernus Pharma (NASDAQ: SUPN) reported Q2 EPS of $0.43, $0.23 better than the analyst estimate of $0.20. Revenue for the quarter came in at $141.3 million versus the consensus estimate of $134.87 million.

GUIDANCE:

Supernus Pharma sees FY2021 revenue of $550-580 million, versus the consensus of $558 million.

For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• RCM Technologies (RCMT) Tops Q2 EPS by 17c
• Calamp Corp. (CAMP) Misses Q2 EPS by 33c